Click here for the full write-up which is a 522kb Adobe Acrobat download.
This is the much anticipated piece from GeroNova Research. Given the cutting edge nature of the research, there are many questions about alpha-lipoic, R-lipoic, S-lipoic and R-dihydrolipoic acids.
In a Pete's Place exclusive, one of the worlds authorities on lipoic speaks out publicly.
Blog comments are enabled - enjoy!
Foreword provided by and courtesy of GeroNova Research.
"Important Notice: The following article is technical and it is essential to understand a few basic principles of pharmacology before delving into it. Although these principles are intuitive it is essential to keep them in mind while reading.
1-The valued properties of a nutrient or medicinal substance are limited by the physical properties and stability of the substance.
2-The ability of the dosage form containing the active substance must disintegrate, dissolve and be absorbed in the body, and not be extensively metabolized by the liver.
3-The valued properties of a nutrient or medicinal substance can only be realized if they can reach significant levels within the body at various sites of action.
4-Therefore, in vitro (an artificial model that isolates particular variables) and animal models suffer severe limitations as being predictive of how a substance will behave in vivo in humans at a particular dose and for a sufficient length of time before being cleared.
5-The amount of physical substance in a tablet or capsule is far less important than the bioavailability (the amount available to living cells) of the substance.
6-Lipoic acid has been used since the mid 1950’s as a medicine or drug to treat diabetic neuropathy. The effective therapeutic doses range from 600-1200 mg/day orally or injected.
7-Lipoic acid has been recommended as dietary supplement at doses of 50-150 mg/day since the early 1990’s.
8-No one has carefully elucidated the relationships between the doses and responses of either the supplemental dose or therapeutic dose or the differences between quick release and sustained release ALA/RLA products.
9-GeroNova has been unable to measure any significant effects at the 50-150 mg dose of ALA or RLA and defines the supplemental dose as containing up to 300mg of RLA and its naturally occurring redox partner R-DHLA.
10- GeroNova proposes a definition for a supplemental dose of RLA/R-DHLA as one that measurably affects biomarkers but is not specifically used to treat a disease.
What follows is an attempt to define these classifications and in so doing address the most relevant issues concerning the discussions over racemic ALA, RLA and R-DHLA and their use as nutritional supplements and as therapeutic agents."
Foreword supplied by and courtesy of GeroNova Research.